Thr280

Site Information
AFSRQTstDDECFIP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 5483997

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Relevant cell line - cell type - tissue:	CLL23LB4 (B lymphocyte) ( 2 ) , lymphocyte ( 1 )

Upstream Regulation
Treatments:	IL-7 ( 1 )

References
1	Queiroz RML, et al. (2022) Proteomic analysis in primary T cells reveals IL-7 alters T cell receptor thresholding via CYTIP/cytohesin/LFA-1 localisation and activation. Biochem J 479, 225-243 35015072 Curated Info
2	Goss V (2005) CST Curation Set: 939; Year: 2005; Biosample/Treatment: cell line, CLL23LB4/-; Disease: chronic lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info